Lamotrigine-associated hemophagocytic lymphohistiocytosis

Nawar Suleman, Metin Ozdemirli, David Weisman

Research output: Contribution to journalArticlepeer-review


Hemophagocytic lymphohistiocytosis (HLH) is a rare and life-threatening disorder of excessive immune activation. It is mostly seen in the paediatric population and is rarely observed in adults. HLH can be inherited or acquired and is commonly triggered by activation of the immune system by an underlying viral infection or in immune system deficiency such as malignancy or underlying rheumatological disease. HLH is a difficult entity to diagnose due to the rarity of this disorder, variable clinical presentation and non-specific clinical and laboratory findings. HLH carries a high mortality if left untreated, and therefore prompt diagnosis and initiation of immunosuppressive, immunomodulatory and cytostatic medications are critical to improve survival in affected patients. Here, we present a case of lamotrigine-associated HLH. To our knowledge, only eight other cases of lamotrigine-associated HLH have been reported in adult patients.

Original languageEnglish (US)
Article numbere238183
JournalBMJ case reports
Issue number1
StatePublished - Jan 6 2021
Externally publishedYes


  • immunology
  • pharmacology and therapeutics

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Lamotrigine-associated hemophagocytic lymphohistiocytosis'. Together they form a unique fingerprint.

Cite this